CEACAM-5 immune stimulating antibody conjugate - Bolt Biotherapeutics
Alternative Names: CEA ISAC; CEA-targeted ISACLatest Information Update: 04 Apr 2026
At a glance
- Originator Bolt Biotherapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 12 Mar 2026 Bolt Therapeutics plans to initiate clinical trials within 18 months of development resumption
- 12 Mar 2026 Suspended - Preclinical for Colorectal cancer in USA (Parenteral) as Bolt Therapeutics seek partnership or funding
- 12 Mar 2026 Suspended - Preclinical for Non-small cell lung cancer in USA (Parenteral) as Bolt Therapeutics seek partnership or funding